Intangible assets—The carrying amounts, accumulated amortization, and net carrying value of our definite-lived intangible assets are presented in the table below (dollars in thousands):


	March 31, 2024				June 30, 2023
	Gross Carrying Amount		Accumulated Amortization		Net Carrying Amount		Gross Carrying Amount		Impairment Charges (1)		Accumulated Amortization		Net Carrying Amount
Customer relationships	$	17,492	$	(10,356)	$	7,136	$	17,492	$	—	$	(8,617)	$	8,875
Trade name	2,680		(2,100)		580		2,680		—		(1,697)		983
Proprietary software	1,042		(875)		167		1,042		—		(758)		284
Non-compete agreements	100		(57)		43		1,292		(533)		(701)		58
Vendor relationships	—		—		—		20,400		(15,111)		(5,289)		—
Total intangible assets	$	21,314	$	(13,388)	$	7,926	$	42,906	$	(15,644)	$	(17,062)	$	10,200

(1) During the year ended June 30, 2023, the Company recorded impairment charges for its long-lived intangible assets recognized as part of the acquisition of a lead distribution company. Refer to the consolidated financial statements in our Annual Report on Form 10-K for additional details.

The Company's intangible assets include those long-lived intangible assets which were recognized at their estimated acquisition date fair values. The Company reviews its long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of such assets may not be recoverable. There were no impairment triggers identified with respect to the Company’s long-lived assets during the three and nine months ended March 31, 2024 and 2023.

For the three months ended March 31, 2024 and 2023, amortization expense related to intangible assets totaled $0.8 million and $1.4 million, respectively, and $2.3 million and $4.2 million for the nine months ended March 31, 2024 and 2023, respectively, recorded in selling, general, and administrative expense in the condensed consolidated statements of comprehensive income (loss). The weighted-average remaining useful life of intangible assets was 2.9 and 3.6 years as of March 31, 2024 and June 30, 2023, respectively.


	Trade Name		Proprietary Software		Non-Compete Agreements		Customer relationships		Total
Remainder fiscal 2024	$	133	$	39	$	5	$	580	$	757
2025	447		128		20		2,316		2,911
2026	—		—		18		2,313		2,331
2027	—		—		—		1,927		1,927


Total	$	580	$	167	$	43	$	7,136	$	7,926

Goodwill—The Company recorded as goodwill the excess of the purchase price over the estimated fair values of identifiable assets and liabilities acquired as part of the acquisitions discussed in Note 2 to the condensed consolidated financial statements. Goodwill is assigned to reporting units that are expected to benefit from the synergies of the business combination as of the acquisition date and becomes identified with that reporting unit in its entirety. As such, the reporting unit as a whole supports the recovery of its goodwill. As of March 31, 2024, the Company’s goodwill balance of $29.1 million was related to the acquisitions of Express Meds and Simple Meds and is all assigned to the Healthcare Services reporting unit and reportable segment.

The Company performs its annual goodwill impairment testing as of April 1, or more frequently if it believes that indicators of impairment exist. During the three and nine months ended March 31, 2024 and 2023, there were no indicators of impairment.